Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dasatinib, although relatively specific for ABL, BCR-ABL and the SFKs, it possesses a broad-spectrum of inhibition of kinases including Kit, PDGFR, EphA receptors and several others (Hantschel et al., 2008).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hantschel et al., 2008
In the citing paper
“We recognize that while dasatinib primarily targets SFKs and BCR-ABL, it also inhibits other kinases including c-KIT, PDGFRβ, EPHA2, among others [41].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [41]
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“In addition to these cases of so-called secondary imatinib resistance, approximately 15% of patients with chronic phase CML do not achieve a complete cytogenetic response on imatinib at the standard dose of 400 mg [4].”
BackgroundGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317 · cited 1×
“DDR1 is emerging as an important player in immunity as well as many tumours, in particular in non-small cell lung cancer [16].”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“Here, a library of *150 to 200 selected kinases are expressed as phage particle fusion proteins and the binding affinity of kinase inhibitors is inferred by competition assays [9,10].”
BackgroundOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796 · cited 2×
“Of these second generation inhibitors, dasatinib (Sprycel, BMS-354825, Bristol-Myers Squibb) has been approved for the treatment of adults with CML and BCR-ABL-positive acute lymphoblastic leukemia with imatinib resistance or intolerance to previous therapy [5].”
BackgroundCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 2×
“imatinib-resistant forms with the exception of the T315I (gatekeeper) mutation [5,6].”
BackgroundThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879 · cited 2×
“Therefore, BCR-ABL is a suitable drug target, and research on this kinase cumulated in the discovery of imatinib (Gleevec1, STI-571), which is currently frontline therapy in CML. Imatinib is a relatively weak inhibitor of BCRABL with an IC50 in the upper nano-molar range, but has remarkable specificity, targeting only…”
BackgroundSelf-citationRix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Self-citationInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554 · cited 2×
“Also in the case of dasatinib, kinases such as the ABL and SRC had been already confirmed and more had been postulated to be potential targets [9].”
Background
Research works printed but not linked: 1
- le Coutre P, Blood
Cited by
Items 201–286 of 286
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon‐14
Kang, J., Lee, J. Y., Park, J. H., & Chang, D. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3830 · Cited by 4
[The advancement of cancer-associated fibroblasts in lung cancer].
Shen, C., & Che, G. (2012) · PubMed Central · doi:10.3779/j.issn.1009-3419.2012.06.11 · Cited by 3
Implications of improved survival in patients with chronic myeloid leukemia: a nursing perspective
Ault, P. S., & Allen‐Bard, S. (2012) · Community Oncology · doi:10.1016/j.cmonc.2012.01.004 · Cited by 3
Back to the future: Host-Targeted Chemotherapeutics for Drug-Resistant TB
Napier, R. J., Shinnick, T. M., & Kalman, D. (2012) · Future Microbiology · doi:10.2217/fmb.12.19 · Cited by 3
“Gleevec is not highly selective, as it binds to Abl and other structurally related tyrosine kinases [44].”
BackgroundMolecular-Targeted Therapy in Refractory or Relapsed Neuroblastoma
Corbacioglu, S. (2015) · Pediatric and adolescent medicine · doi:10.1159/000382098 · Cited by 3
Ansar, S., & Vetrivel, U. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13705 · Cited by 3
“…et al., 2006; wild form of EGFR with seven interaction pattern was also observed), EphB4 (Y774E_A803V_V870I; Tröster et al., 2018), HCK (Q523E, Q524E, Q525I; functional disability due to this mutation is not reported, hence was considered as wild type; Hantschel et al., 2008) Figure 5b & Table S6.”
BackgroundRoberts, K., Deininger, M. W., Hildebrandt, G. C., Gackenbach, B. K., & Krem, M. M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1808210 · Cited by 3
“In addition to inhibiting BCR-ABL1, dasatinib also targets SRC-family kinases, platelet-derived growth factor receptor b (PDGFRb), KIT, many of the ephrin receptor family members, the CSF1R, and others [7,8].”
BackgroundInfluentialGudimetla, K., & Orsu, P. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns3.7888 · Cited by 3
“[44] An extensive literature survey explored the cellular effect of natural flavonoids on the MAPK signaling cascade, PI3K/AKT signaling pathway, and the modulatory effect on drug resistance.”
BackgroundEnhancing cognate target elution efficiency in gel-free chemical proteomics
Radic-Sarikas, B., Rix, U., Stukalov, A., Gridling, M., Müller, A. C., Colinge, J., Superti‐Furga, G., & Bennett, K. L. (2015) · EuPA Open Proteomics · doi:10.1016/j.euprot.2015.09.002 · Cited by 2
Self-citationAmbrogio, F., Poli, M. A., Lospalluti, L., Lettini, T., Cassano, N., Vena, G. A., Ingravallo, G., Cazzato, G., & Foti, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010032 · Cited by 2
“Dasatinib acts as a multikinase inhibitor against numerous targets, including BCR-ABL, SRC family kinases, KIT, PDGFR, DDR1, DDR2, ephrin receptor tyrosine kinases, TEC family kinases, epidermal growth factor receptor (EGFR), ERK-1/2 and STAT-5 [5,11–13].”
BackgroundTridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00012-3 · Cited by 2
Butterfield, J. H. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709620987691 · Cited by 2
Marquardt, R., Andreas, N., Herrnberger, R., Küchler, C., Hornung, K., Nieswandt, B., Groth, M., Jordan, P. M., Werz, O., Drube, J., et al. (2025) · Immunology · doi:10.1111/imm.70055 · Cited by 1
“Given that Nilotinib does not target SFKs (e.g., Lyn) [46], we assume a yet unidentified target of Nilotinib which acts as an upstream activator for SFKs (e.g., Lyn) in MCs. Inhibition of this target indirectly blocks Lyn activation which results in an Abl1-dependent re-expression of ABCB1.”
Therapy of Newly Diagnosed and Chronic‐Phase Chronic Myeloid Leukemia
Hochhaus, A. (2010) · Wiley eBooks · doi:10.1002/9781444327359.ch22 · Cited by 1
Small Molecule Inhibitors of Discoidin Domain Receptors (DDRs)
Lu, X., & Ding, K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6383-6_10 · Cited by 1
Pulmonary Hypertension Induced by Anticancer Drugs
Mercurio, V., Agnetti, G., Pagliaro, P., & Tocchetti, C. G. (2018) · Current clinical pathology · doi:10.1007/978-3-319-93402-0_14 · Cited by 1
Utilizing small molecules in chemical genomics: Toward high-throughput (HT) approaches
Dormán, G., & Darvas, F. (2013) · CRC Press eBooks · doi:10.1201/b12957-2 · Cited by 1
Gao, X., & Arodź, T. (2012) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/2382936.2383037 · Cited by 1
Cross Resistance: Treatment and Modeling
Komarova, N. L., & Wodarz, D. (2013) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-1-4614-8301-4_8 · Cited by 1
Target therapies-induced Cardiotoxicity
Lazzari, L., Paolis, M. D., Bovelli, D., & Boschetti, E. (2013) · European Oncology & Haematology · doi:10.17925/eoh.2013.09.1.56 · Cited by 1
Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
Hamada, T., Iriyama, N., Takahashi, H., Miura, K., Uchino, Y., Nakagawa, M., Hatta, Y., & Takei, M. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0670-0 · Cited by 1
Switch Pocket Kinase: An Emerging Therapeutic Target for the Design of Anticancer Agents
Kaur, C., Sharma, B., & Nepali, K. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220404081302 · Cited by 1
Computational approaches in high-throughput proteomics data analysis
Lahesmaa‐Korpinen, A. (2012) · Työväentutkimus Vuosikirja · Cited by 1
IGF-1 activates c-Abl to regulate PTPα tyrosine phosphorylation and cell migration
Khanna, R. S. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0071893 · Cited by 1
Broad kinase inhibition mitigates early neuronal dysfunction and cognitive deficits in tauopathyPreprint
Koren, S. A., Hamm, M. J., Cloyd, R., Fontaine, S. N., Chishti, E. A., Lanzillotta, C., Rodriguez-Rivera, J., Ingram, A., Bell, M. C., Escobar, S. M. G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.31.229583 · Cited by 1
Drug response profiling to identify new targets in refractory leukemia
Frismantas, V. (2016) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-204764 · Cited by 1
dos Santos, A. P. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Effects of Small Molecules and Cytokine Signalling on NLRP3 Inflammasome Activation
Ćiković, T. (2019) · Cited by 1
Delord, M. (2015) · theses.fr (ABES) · doi:10.70675/7de4a510zbee9z45c4za56aza35e488000e7 · Cited by 1
Leibnitz, A. (2014) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-4492
Effects of The BCR-ABLl Oncogene on DNA Damage and Repair
Burke, B. A. (2010) · ScholarlyCommons (University of Pennsylvania)
Wang, L., O’Leary, H. A., & Gibson, L. F. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0711-0_18
Hochhaus, A., Overkamp, F., Lange, T., Mohr, A., Ottmann, O. G., le Coutre, P., & Haferlach, T. (2010) · Der Onkologe · doi:10.1007/s00761-010-1894-7
“Dasatinib ist ein Multikinaseinhibitor, der eine sehr hohe Potenz gegenüber BCR-ABL aufweist (in vitro 325-fach potenter als Imatinib) und zusätzlich zu BCR-ABL auch ein breites Spektrum anderer Kinasen hemmt [24].”
BackgroundSchmid, J. O. (2013) · University writing server of the University of Hohenheim (Universität Hohenheim)
Konopka, L., Hellmann, A. R., Komarnicki, M. A., & Wąsak-Szulkowska, E. (2012) · Acta Haematologica Polonica · doi:10.1016/s0001-5814(12)70006-3
Aspects on long-term treatment with tyrosine kinase inhibitors in Chronic myeloid leukemia
Jönsson, S. (2011) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Naturwissenschaften, F., & Fischer-Bosch-Institut, M. (2011)
Functional proteomics of Bcr-Abl signaling
Brehme, M. (2009) · University of Vienna · doi:10.25365/thesis.3955
Muranyi, A. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0070894
Lamontanara, A. J. (2016) · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · doi:10.5075/epfl-thesis-6987
Nilotinib efficacy in a patient resistant to imatinib
Luciano, L. (2015) · Clinical Management Issues · doi:10.7175/cmi.v4i5s.1093
ROR1 expression and function in B-cell malignancies
Bicocca, V. T. (2015) · doi:10.6083/m4j964cr
- Utilizing small molecules in chemical genomics: Toward high-throughput (HT) approaches
Dormán, G., & Darvas, F. (2013) · CRC Press eBooks · doi:10.1201/b12957-4
How point mutations confer resistance in BCR-ABL: a computational study
Clapton, G. (2015) · ePrints Soton (University of Southampton)
Effects of Interferon alpha on mouse and human hematopoietic stem cells
Wurzer, S. (2012) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00013884
The Effects of Discoidin Domain Receptor 1 on Macrophage Phenotype in Vascular Inflammatory Disease
Fung, W. C.-Y. (2015) · TSpace (University of Toronto)
Targeting Fusion Genes for Cancer Therapy
Roy, N. K., Bordoloi, D., Padmavathi, G., & Kunnumakkara, A. B. (2017) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789813200944_0021
Porter, V. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0363913
Study of the Mechanism of Action for Ru(II) Polypyridyl Complexes as Potential Anticancer Agents
Sun, Y. (2018) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2018.184
Schmachtenberg, A.-J. (2018) · edoc Publication server (Humboldt University of Berlin) · doi:10.18452/19369
Masche, U. (2009) · pharma-kritik · doi:10.37667/pk.2009.251
Tridente, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809400-6.00029-9
Functional characterization of Gpnmb in inflammatory and metabolic diseases
Nickl, B. (2020) · edoc Publication server (Humboldt University of Berlin) · doi:10.18452/21430
Signaling Mechanisms of Down Syndrome Cell Adhesion Molecule in Presynaptic Arbor Size Control.
Sterne, G. R. (2016) · Deep Blue (University of Michigan)
Targeting MYC in B-cell haematologic malignancies
Martínez-Martín, S. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Activation-induced cytidine deaminase(AID)を介するメシル酸イマチニブのB細胞分化抑制作用の解析
川俣, 豊. (2013) · Institutional Repositories DataBase (IRDB) · doi:10.15083/00005469
Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Ottmann, O. G. (2021) · Springer eBooks · doi:10.1007/978-3-030-85147-7_9
Improving patient survival by direct targeting of chimeric protein-protein interaction networksPreprint
Tagore, S., & Frenkel‐Morgenstern, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.24.485646
Looking into the toxicity potential and clinical benefits of tyrosine kinase inhibitors (TKIs)
Ajideh, R., Kamyab, H., & Yazdi, M. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00029-4
Sylvester, J. E., & Kron, S. J. (2023) · doi:10.1158/1535-7163.c.6531552
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00002-7
Formulation and Evaluation of Immediate Release Dasatinib Film Coated Tablet
senapathi, C., vemuru, S., Sadam, D. L., Boddu, V., & Chennupalli, V. G. (2025) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2025.v07i03.49054
Reshape memory T cell landscape in CML patients' blood by tyrosine kinase inhibitors.
Kareem, H. A., & Ghadi, H. H. (2025) · PubMed Central · doi:10.22088/cjim.16.4.755
“This research could potentially lead to the development of more targeted anti-leukemia immunotherapies by further exploring the underlying mechanisms of TEM and TEF subset dysfunction in CML patients (23).”
Krauss, C. A., & Justus Liebig University Giessen (2020) · University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) · doi:10.22029/jlupub-14866
Ntari, L., Nikolaou, C., Kranidioti, K., Papadopoulou, D., Christodoulou‐Vafeiadou, E., Chouvardas, P., Meier, F. M. P., Geka, C., Denis, M. C., Karagianni, N., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14478414
Filho, T. P. D. A. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Modernising toxicity monitoring in chronic myeloid leukaemia
Smit, Y. (2026) · Radboud University Press eBooks · doi:10.54195/9789465151106
Innovations thérapeutiques non vasodilatatrices dans l'hypertension artérielle pulmonaire
Chaumais, M. (2012) · theses.fr (ABES) · doi:10.70675/f98576e9z0468z4cf4zbadbzf6476fd91579
スプリットルシフェラーゼ再構成技術を用いた細胞融合評価法の開発
Li, Q. (2018) · Institutional Repositories DataBase (IRDB) · doi:10.15083/0002001487
Fonctions oncogéniques de STAT5 : rôle dans la régulation du métabolisme oxydatif
Bourgeais, J. (2015) · theses.fr (ABES) · doi:10.70675/642a7bdcz3eb5z47fcza4fez4dd048c937e2
Lecacheur, M. (2021) · theses.fr (ABES) · doi:10.70675/9c0b4d17zd8d8z498ezb534z3096acf22d56
Identification of an Inhaled Pulmonary Selective PDGFR Inhibitor with Sustained Target Engagement
Marsboom, G., Lu, T., Hong, Z., Holt, K., Edmondson, M., Huang, C.-H., Rosario, A. M. D., Ibrahim, S., Wong, V. D., Harbut, M., et al. (2026) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1177/19412711261449635
Takahashi, N., Kim, D. H., Kim, I., Du, X., Lee, S., Hu, Y., Kikushige, Y., Jiang, Q., Wang, Y., Chen, S., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72019
BindingDB (2013) · UC San Diego · doi:10.7270/q21r6rv3
Smit, Y., Timmerman, J., Currie, A., Soltan, H., Abma, I. L., Janssen, J. J. W. M., Posthuma, E. F. M., Fijten, R., Bronkhorst, E. M., Dekker, A. L. A. J., et al. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11371-w
Joo, V., Petrovas, C., de Leval, L., Noto, A., Obeid, M., Fenwick, C., & Pantaleo, G. (2023) · doi:10.3389/fimmu.2023.1213375.s001
Daniels, H. G., Knicely, B. G., Miller, A. K., Thompson, A., Plattner, R., & Goellner, E. M. (2022) · doi:10.3389/fgene.2022.940073.s004
Regulation of the Apoptosome in Cancer
Kim, J. (2012) · DukeSpace (Duke University)
Metadata
- Authors
- Hantschel, O., Rix, U., & Superti-Furga, G.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 49
- Issue
- 4
- Pages
- 615-619
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2034862875
- Cited by
- 256
- References
- 17
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 14 · 2022: 15 · 2021: 14 · 2020: 21 · 2019: 10 · 2018: 16 · 2017: 19 · 2016: 10 · 2015: 17 · 2014: 15 · 2013: 19 · 2012: 23
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BCR-ABL tyrosine kinase inhibitors, imatinib, nilotinib, dasatinib, chronic myeloid leukemia, target specificity, imatinib resistance, second-generation tyrosine kinase inhibitors
- MeSH terms
- Imatinib Mesylate, Dasatinib, Benzamides, Humans, Piperazines, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Drug Delivery Systems, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.